Physicians' Academy for Cardiovascular Education

Greater reduction of LV mass index with ARNI than with ARB in hypertensive patients

Literature - Schmieder RE, Wagner F, Mayr M, et al. - Eur Heart J 2017; published online ahead of print

Main results

Conclusion

In patients with hypertension, treatment with sacubitril/valsartan was associated with superior reductions of LV mass after 12 and 52 weeks and central PP after 52 weeks compared to treatment with olmesartan, suggesting that sacubitril/valsartan may lead to a better cardiovascular prognosis in this patient population than olmesartan.

References

Show references

Find this article online at Eur Heart J

Share this page with your colleagues and friends: